Chaudhary R K, Andonov A, MacLean C
Laboratory for Viral Hepatitis, Health and Welfare Canada, Ottawa, Ontario.
J Clin Lab Anal. 1993;7(3):164-7. doi: 10.1002/jcla.1860070306.
The newly developed immunoblot assay, RIBA SIA (recombinant and synthetic polypeptide immunoblot assay), Chiron, Calif., was compared with the commercially available second generation recombinant immunoblot assay (RIBA-2) for the detection of antibody to hepatitis C virus (anti-HCV). The two immunoblot tests were also compared with the polymerase chain reaction (PCR) for the detection of HCV RNA. Ninety-one percent of samples reactive by RIBA-2 were positive for anti-HCV by RIBA SIA. A total of 31% of RIBA-2 indeterminate samples became reactive by RIBA SIA, 24% became non-reactive, and 45% remained the same. Samples reactive by RIBA-2 or SIA from different risk groups, were mostly positive (67-100%) by PCR for HCV RNA. All indeterminate samples from hemophiliacs and intravenous drug users were PCR positive. RIBA SIA is more sensitive and specific than RIBA-2 and correlates well with PCR results.
将加利福尼亚州奇龙公司新开发的免疫印迹检测法（重组和合成多肽免疫印迹检测法，即RIBA SIA）与市售的第二代重组免疫印迹检测法（RIBA - 2）用于检测丙型肝炎病毒抗体（抗 - HCV）进行比较。还将这两种免疫印迹检测法与用于检测HCV RNA的聚合酶链反应（PCR）进行比较。RIBA - 2检测呈反应性的样本中，91%通过RIBA SIA检测抗 - HCV呈阳性。RIBA - 2检测结果不确定的样本中，共有31%通过RIBA SIA检测变为反应性，24%变为无反应性，45%保持不变。来自不同风险组的通过RIBA - 2或SIA检测呈反应性的样本，大多通过PCR检测HCV RNA呈阳性（67 - 100%）。血友病患者和静脉吸毒者的所有检测结果不确定的样本PCR检测均为阳性。RIBA SIA比RIBA - 2更敏感、更特异，且与PCR结果相关性良好。
